StockData
Viatris Inc logo

Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/309% below fair value
$20.45−0.29 (-1.40%)

Close on Nov 17, 2026Market cap $23.49BP/E –Yield 2.35%

Viatris total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Viatris's total debt was $13.35B at Jun 30, 2026. For fiscal 2025 it was $14.41B, up 2.6% from the year before. The highest annual figure on record is $24.69B in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.41B+2.6%
FY2024Dec 31, 2024$14.04B-22.5%
FY2023Dec 31, 2023$18.12B-5.9%
FY2022Dec 31, 2022$19.27B-10.7%
FY2021Dec 31, 2021$21.58B-12.6%
FY2020Dec 31, 2020$24.69B+94.8%
FY2019Dec 31, 2019$12.67B–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.35B-7.7%
Q1 FY2026Mar 31, 2026$14.34B+1.1%
Q4 FY2025Dec 31, 2025$14.41B+2.6%
Q3 FY2025Sep 30, 2025$14.43B-8.3%
Q2 FY2025Jun 30, 2025$14.46B-15.4%
Q1 FY2025Mar 31, 2025$14.18B-21.1%
Q4 FY2024Dec 31, 2024$14.04B-22.5%
Q3 FY2024Sep 30, 2024$15.74B-14.3%
Q2 FY2024Jun 30, 2024$17.09B-8.0%
Q1 FY2024Mar 31, 2024$17.96B-3.3%
Q4 FY2023Dec 31, 2023$18.12B-5.9%
Q3 FY2023Sep 30, 2023$18.38B-5.7%
Q2 FY2023Jun 30, 2023$18.57B-7.0%
Q1 FY2023Mar 31, 2023$18.57B-13.1%
Q4 FY2022Dec 31, 2022$19.27B-10.7%
Q3 FY2022Sep 30, 2022$19.48B-10.4%
Q2 FY2022Jun 30, 2022$19.97B-13.4%
Q1 FY2022Mar 31, 2022$21.36B-12.3%
Q4 FY2021Dec 31, 2021$21.58B-12.6%
Q3 FY2021Sep 30, 2021$21.74B+88.4%
Q2 FY2021Jun 30, 2021$23.07B+102.6%
Q1 FY2021Mar 31, 2021$24.36B+92.2%
Q4 FY2020Dec 31, 2020$24.69B–
Q3 FY2020Sep 30, 2020$11.54B–
Q2 FY2020Jun 30, 2020$11.39B–
Q4 FY2019Dec 31, 2019$12.67B–

More Viatris figures

See a number that looks wrong?